Abstract - 603255 Disclosed is the compound 2-(3-(cyclopropylmethyl)-2-oxo-imidazolidin-1-yl)-4-methyl-N-(pyridin-3-ylmethyl)thiazole-5-carboxamide or a pharmaceutically acceptable salt thereof. Further disclosed is a pharmaceutical composition comprising a therapeutically effective amount of the compound 2-(3-(cyclopropylmethyl)-2-oxoimidazolidin-1-yl)-4-methyl-N-(pyridin-3-ylmethyl)thiazole-5-carboxamide or a pharmaceutically acceptable salt thereof optionally in combination with a therapeutic...

This invention relates to solid formulations for the oral delivery of live microbial cells which comprise dried viable cells and small amounts of a bile acid binding agent, for example, an anion exchange resin such as cholestyramine. The presence of bile acid binding agents in the formulation significantly increases the survival of the cells in the intestinal tract and facilitates delivery of the viable cells to the intestine.

This invention relates to solid formulations for the oral delivery of live microbial cells which comprise dried viable cells and small amounts of a bile acid binding agent, for example, an anion exchange resin such as cholestyramine. The presence of bile acid binding agents in the formulation significantly increases the survival of the cells in the intestinal tract and facilitates delivery of the viable cells to the intestine.

The present invention relates to a pharmaceutical composition containing orlistat and a pharmaceutically acceptable bile acid sequestrant selected from a group comprising cholestyramine colestipol colesevelam colestimide sevelamer cellulose and dextran derivatives starch and starch derivatives and pharmaceutically acceptable salts thereof. The invention also relates to orlistat together with the bile acid sequestrant as a combined composition for simultaneous separate or sequential administratio...

The present invention relates to pretreating individuals with an effective amount of a flush inhibiting agent for a sufficient period of time prior to the start of single daily dose nicotinic acid therapy to reduc e the capacity of nicotinic acid to induce flushing reactions in such individuals during nicotinic acid therapy. In accordance with the present invention the flush inhibiting agents are administered orally one to four times a day and preferably one to two times per day for between abou...

The present invention relates to pretreating individuals with an effective amount of a flush inhibiting agent for a sufficient period of time prior to the start of single daily dose nicotinic acid therapy to reduce the capacity of nicotinic acid to induce flushing reactions in such individuals during nicotinic acid therapy. In accordance with the present invention the flush inhibiting agents are administered orally one to four times a day and preferably one to two times per day for between about...

Kompozice obsahujcholestyramin a rob prostoleje s vynikaji organolepticki znaky se dostanou t se cholestyramin a zrna robu v hmotnostn pomu 118 a29 za pdavku obilnh otrub jako plnico nidla a poppadaromaticklky sms 10 a35% hmotnostni vody poto na vhozlky na homogennvlhkou hmotu ktero hmota se vytlaje na provazec pmteplota mena ve hmotve vytlavachlav je 105 a180.sup.o.n.C a tlak men ve vytlavachlav je 30 a70 MPa. a nledujsunse provza teploty nad 100.sup.o.n.C k dosanobsahu vlhkosti rovno nebo nio...

The present invention relates to pretreating individuals with an effective amount of a flush inhibiting agent for a sufficient period of time prior to the start of single daily dose nicotinic acid therapy to reduce the capacity of nicotinic acid to induce flushing reactions in such individuals during nicotinic acid therapy. In accordance with the present invention the flush inhibiting agents are administered orally one to four times a day and preferably one to two times per day for between about...